Prevention of Microalbuminuria in Diabetes Mellitus: Results of the ROADMAP Trial

被引：0
|
作者：
Grassi, Guido [1 ]
Mancia, Giuseppe [2 ]
机构：
[1] Osped San Gerardo, Med Clin, I-20052 Milan, Italy
[2] Univ Milano Bicocca, Osped San Gerardo Tintori Monza, Med Clin, Milan, Italy
来源：
CURRENT HYPERTENSION REPORTS | 2011年 / 13卷 / 04期
关键词：
Hypertension; Blood pressure; Olmesartan; ARBs; Diabetes mellitus; Type; 2; diabetes; Microalbuminuria; Albuminuria; ROADMAP trial; Kidney disease; End-organ damage; Cardiovascular effects; Clinical trial;
D O I：
10.1007/s11906-011-0209-8
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：265 / 267
页数：3
相关论文
共 50 条
  • [1] Prevention of Microalbuminuria in Diabetes Mellitus: Results of the ROADMAP Trial
    Guido Grassi
    Giuseppe Mancia
    Current Hypertension Reports, 2011, 13 : 265 - 267
  • [2] Prevention of microalbuminuria in type 2 diabetes (ROADMAP Trial)
    Haller, H.
    Januszewicz, A.
    Mimran, A.
    Menne, J.
    Rabelink, T.
    Ritz, E.
    Rump, L. C.
    Ruilope, L. M.
    Viberti, G. C.
    EUROPEAN HEART JOURNAL, 2010, 31 : 321 - 321
  • [3] Prevention of microalbuminuria in type 2 diabetes (ROADMAP Trial)
    Haller, H.
    Ritz, E.
    Ruilope, L.
    Rabelink, T.
    Viberti, G.
    DIABETOLOGIA, 2010, 53 : S98 - S99
  • [4] PREVENTION OF MICROALBUMINURIA IN TYPE 2 DIABETES (ROADMAP TRIAL)
    Haller, H.
    Ito, S.
    Izzo, J. L.
    Januszewicz, A.
    Katayama, S.
    Menne, J.
    Mimran, A.
    Rabelink, T. J.
    Ritz, E.
    Ruilope, L. M.
    Rump, L. C.
    Viberti, G.
    JOURNAL OF HYPERTENSION, 2010, 28 : E233 - E233
  • [5] The ROADMAP trial: olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Grassi, Guido
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (15) : 2421 - 2424
  • [6] Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP)
    Ritz, Eberhard
    POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2011, 121 (05): : 145 - 147
  • [7] Preventing microalbuminuria in patients with diabetes: rationale and design of the Randornised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study
    Haller, H
    Viberti, GC
    Mimran, A
    Remuzzi, G
    Rabelink, AJ
    Ritz, E
    Rump, LC
    Ruilope, LM
    Katayama, S
    Ito, S
    Izzo, JL
    Januszewicz, A
    JOURNAL OF HYPERTENSION, 2006, 24 (02) : 403 - 408
  • [8] Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes
    Chatzikyrkou, Christos
    Menne, Jan
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (09) : 1087 - 1092
  • [9] PREVENTION OF MICROALBUMINURIA: PREDICTORS FOR A GOOD RESPONSE TO OLMESARTAN TREATMENT (ROADMAP TRIAL)
    Haller, H.
    Ito, S.
    Izzo, J. L.
    Januszewicz, A.
    Katayama, S.
    Menne, J.
    Mimran, A.
    Rabelink, T. J.
    Ritz, E.
    Ruilope, L. M.
    Rump, L. C.
    Viberti, G.
    JOURNAL OF HYPERTENSION, 2010, 28 : E275 - E275
  • [10] Prevention of microalbuminuria: predictors for a good response to olmesartan treatment (ROADMAP Trial)
    Viberti, G.
    Ritz, E.
    Ruilope, L.
    Haller, H.
    DIABETOLOGIA, 2010, 53
12345